SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –
– Additional data..